Toll样受体在代谢相关脂肪性肝病中的基础研究
Basic Research on Toll-Like Receptors in Metabolism-Related Fatty Liver Disease
DOI: 10.12677/ACM.2023.1361241, PDF,    科研立项经费支持
作者: 王晓阳, 叶丹阳:潍坊医学院,内分泌科,山东 潍坊;边家祥:潍坊医学院,神外科,山东 潍坊;程丽霞*:潍坊市人民医院,内分泌科,山东 潍坊
关键词: 代谢相关脂肪性肝病(MAFLD)非酒精性脂肪性肝炎(NASH)肠道微生物群高脂肪饮食Toll样受体(TLR)Metabolism-Related Fatty Liver Disease (MAFLD) Nonalcoholic Steatohepatitis (NASH) Gut Microbiota High-Fat Diet Toll-Like Receptor (TLR)
摘要: 代谢相关脂肪性肝病(metabolic associated fatty liver disease, MAFLD)是目前世界上最主要的肝脏疾病,对该病发病机制进行分析,能够看出其之所以会出现肝病,并非是由于酒精引起的肝损伤而是因为肝内过度沉积脂肪产生的一种临床病理综合征。流行病学研究的结果表明超重和胰岛素抵抗是MAFLD发展的关键风险因素,而临床和实验研究结果也表明,肠道微生物群组成和肠道屏障的改变可能有助于疾病的发生和发展。随着社会的逐渐发展,目前社会居民的生活质量得到显著改善,饮食习惯也发生极大变化,该病的发病率每年都在快速增长,构成了全世界肝脏纤维化的主要原因,逐渐对人体健康构成威胁,并已成为世界范围内的一大卫生问题。近年来,许多学者已经确认了固有免疫系统的活化对MAFLD的发展起到了重要的作用,Toll样受体(Toll-like receptor, TLR)途径是其中关键一环。TLR在各种肝病中均表现为异常,其作用机制是通过调节TNF-α、IL-1β的表达,从而加剧肝组织的炎症反应。
Abstract: Metabolic associated fatty liver disease (MAFLD) is currently the world’s leading liver disease. By analysis of the pathogenesis of the disease, it can be seen that the reason for liver disease is not due to liver damage caused by alcohol, but because of a clinicopathological syndrome produced by ex-cessive deposition of fat in the liver. The results of epidemiological studies suggest that overweight and insulin resistance are key risk factors for the development of MAFLD, while clinical and exper-imental studies have also suggested that alterations in gut microbiota composition and intestinal barrier may contribute to the onset and progression of the disease. With the gradual development of society, the quality of life of social residents has been significantly improved, eating habits have also undergone great changes, the incidence of the disease is growing rapidly every year, constitut-ing the main cause of liver fibrosis in the world, gradually posing a threat to human health, and has become a major health problem worldwide. In recent years, many scholars have confirmed that the activation of the innate immune system plays an important role in the development of MAFLD, and the Toll-like receptor (TLR) pathway is a key part of this. TLR is abnormal in various liver diseases, and its mechanism of action is to increase the inflammatory response of liver tissue by regulating the expression of TNF-α and IL-1β.
文章引用:王晓阳, 叶丹阳, 边家祥, 程丽霞. Toll样受体在代谢相关脂肪性肝病中的基础研究[J]. 临床医学进展, 2023, 13(6): 8877-8883. https://doi.org/10.12677/ACM.2023.1361241

参考文献

[1] Eslam, M., Newsome, P.N., Sarin, S.K., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
[2] Kuchay, M.S., Choudhary, N.S., Gagneja, S., et al. (2021) Low Skeletal Muscle Mass Is Associated with Liver Fibrosis in Individuals with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Journal of Gastroenterology and Hepatology, 36, 3204-3211. [Google Scholar] [CrossRef] [PubMed]
[3] Dhanasekaran, R. and Felsher, D.W. (2019) A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. Hepatology, 70, 1056-1058. [Google Scholar] [CrossRef] [PubMed]
[4] Doycheva, I., Issa, D., Watt, K.D., Lopez, R., Rifai, G. and Alkhouri, N. (2018) Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. Journal of Clinical Gastroenterology, 52, 339-346. [Google Scholar] [CrossRef
[5] Younossi, Z.M., Stepanova, M., Ong, J., et al. (2021) Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clinical Gastroenterology and Hepatology, 19, 580-589.e5. [Google Scholar] [CrossRef] [PubMed]
[6] Tsan, M.F. and Gao, B. (2004) Endogenous Ligands of Toll-Like Receptors. Journal of Leukocyte Biology, 76, 514-519. [Google Scholar] [CrossRef] [PubMed]
[7] Walton, K.A., Cole, A.L., Yeh, M., et al. (2003) Specific Phospholipid Oxidation Products Inhibit Ligand Activation of Toll-Like Receptors 4 and 2. Arteriosclerosis, Thrombosis, and Vascu-lar Biology, 23, 1197-1203. [Google Scholar] [CrossRef
[8] Walton, K.A., Hsieh, X., Gharavi, N., et al. (2003) Receptors Involved in the Oxidized 1-Palmitoyl-2-arachidonoyl- sn-glycero-3-phosphorylcholine-Mediated Synthesis of Interleukin-8. A Role for Toll-Like Receptor 4 and a Glycosylphosphatidylinositol-Anchored Protein. Journal of Biolog-ical Chemistry, 278, 29661-29666. [Google Scholar] [CrossRef
[9] Bäckhed, F., Ding, H., Wang, T., et al. (2004) The Gut Microbiota as an Environmental Factor That Regulates Fat Storage. Proceedings of the National Academy of Sciences of the United States of America, 101, 15718-15723. [Google Scholar] [CrossRef] [PubMed]
[10] Betanzos-Cabrera, G., Estrada-Luna, D., Belefant-Miller, H. and Cancino-Díaz, J.C. (2012) Mice Fed with a High Fat Diet Show a Decrease in the Expression of Toll Like Receptor (TLR)2 and TLR6 mRNAs in Adipose and Hepatic Tissues. Nutrición Hospitalaria, 27, 1196-1203.
[11] Kanuri, G., Ladurner, R., Skibovskaya, J., et al. (2015) Expression of Toll-Like Receptors 1-5 but Not TLR 6-10 Is Elevated in Liv-ers of Patients with Non-Alcoholic Fatty Liver Disease. Liver International, 35, 562-568. [Google Scholar] [CrossRef] [PubMed]
[12] Castrillo, A., Joseph, S.B., Vaidya, S.A., et al. (2003) Crosstalk between LXR and Toll-Like Receptor Signaling Mediates Bacterial and Viral Antagonism of Cholesterol Metabolism. Molecular Cell, 12, 805-816. [Google Scholar] [CrossRef
[13] Ratziu, V., Harrison, S.A., Francque, S., et al. (2016) Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening. Gastroenterology, 150, 1147-1159.e5. [Google Scholar] [CrossRef] [PubMed]
[14] Mouries, J., Brescia, P., Silvestri, A., et al. (2019) Microbio-ta-Driven Gut Vascular Barrier Disruption Is a Prerequisite for Non-Alcoholic Steatohepatitis Development. Journal of Hepatology, 71, 1216-1228. [Google Scholar] [CrossRef] [PubMed]
[15] Shi, W., Wang, X., Tangchitpiyanond, K., Wong, J., Shi, Y. and Lusis, A.J. (2002) Atherosclerosis in C3H/HeJ Mice Reconstituted with Apolipoprotein E-Null Bone Marrow. Arterio-sclerosis, Thrombosis, and Vascular Biology, 22, 650- 655. [Google Scholar] [CrossRef
[16] Singh, A., Boden, G. and Rao, A.K. (2015) Tissue Factor and Toll-Like Receptor (TLR)4 in Hyperglycaemia-Hyper- insulinaemia. Effects in Healthy Subjects, and Type 1 and Type 2 Diabetes Mellitus. Thrombosis and Haemostasis, 113, 750-758. [Google Scholar] [CrossRef
[17] Martínez-Montoro, J.I., Kuchay, M.S., Balaguer-Román, A., et al. (2022) Gut Microbiota and Related Metabolites in the Pathogenesis of Nonalcoholic Steatohepatitis and Its Resolution after Bariatric Surgery. Obesity Reviews, 23, e13367. [Google Scholar] [CrossRef] [PubMed]
[18] Del Chierico, F., Nobili, V., Vernocchi, P., et al. (2017) Gut Microbiota Profiling of Pediatric Nonalcoholic Fatty Liver Disease and Obese Patients Unveiled by an Integrated Meta-Omics-Based Approach. Hepatology, 65, 451-464. [Google Scholar] [CrossRef] [PubMed]
[19] Yamamoto, M. and Takeda, K. (2010) Current Views of Toll-Like Receptor Signaling Pathways. Gastroenterology Research and Practice, 2010, Article ID: 240365. [Google Scholar] [CrossRef] [PubMed]
[20] Ye, D., Li, F.Y., Lam, K.S., et al. (2012) Toll-Like Receptor-4 Mediates Obesity-Induced Non-Alcoholic Steatohepatitis through Activation of X-Box Binding Protein-1 in Mice. Gut, 61, 1058-1067. [Google Scholar] [CrossRef] [PubMed]
[21] Zhang, R.N., Pan, Q., Zhang, Z., Cao, H.X., Shen, F. and Fan, J.G. (2015) Saturated Fatty Acid Inhibits Viral Replication in Chronic Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease by Toll-Like Receptor 4-Mediated Innate Immune Response. Hepatitis Monthly, 15, e27909. [Google Scholar] [CrossRef] [PubMed]
[22] Zhou, Z., Zeng, C., Nie, L., et al. (2017) The Effects of TLR3, TRIF and TRAF3 SNPs and Interactions with Environmental Factors on Type 2 Diabetes Mellitus and Vascular Complications in a Han Chinese Population. Gene, 626, 41-47. [Google Scholar] [CrossRef] [PubMed]
[23] Aragonès, G., Colom-Pellicer, M., Aguilar, C., et al. (2020) Cir-culating Microbiota-Derived Metabolites: A Liquid Biopsy. International Journal of Obesity (London), 44, 875-885. [Google Scholar] [CrossRef] [PubMed]
[24] Baumann, A., Nier, A., Hernández-Arriaga, A., et al. (2021) Toll-Like Receptor 1 as a Possible Target in Non-Alcoholic Fatty Liver Disease. Scientific Reports, 11, Article No. 17815. [Google Scholar] [CrossRef] [PubMed]
[25] Zu, L., He, J., Jiang, H., Xu, C., Pu, S. and Xu, G. (2009) Bac-terial Endotoxin Stimulates Adipose Lipolysis via Toll- Like Receptor 4 and Extracellular Signal-Regulated Kinase Path-way. Journal of Biological Chemistry, 284, 5915-5926. [Google Scholar] [CrossRef
[26] Pan, X., Chiwanda Kaminga, A., Liu, A., Wen, S.W., Chen, J. and Luo, J. (2020) Chemokines in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Frontiers in Immunology, 11, Article No. 1802. [Google Scholar] [CrossRef] [PubMed]
[27] Carpino, G., Del Ben, M., Pastori, D., et al. (2020) Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology, 72, 470-485. [Google Scholar] [CrossRef] [PubMed]
[28] Zhang, Z., Xu, X., Tian, W., et al. (2020) ARRB1 Inhibits Non-Alcoholic Steatohepatitis Progression by Promoting GDF15 Maturation. Journal of Hepatology, 72, 976-989. [Google Scholar] [CrossRef] [PubMed]
[29] Bertran, L., Jorba-Martin, R., Barrientos-Riosalido, A., et al. (2022) New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 23, Article No. 7442. [Google Scholar] [CrossRef] [PubMed]
[30] Tsai, H.C., Chang, F.P., Li, T.H., et al. (2019) Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. BioMed Research International, 2019, Article ID: 6740616. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, X., Fan, L., Wu, J., et al. (2019) Macrophage p38α Promotes Nutritional Steatohepatitis through M1 Polarization. Journal of Hepatology, 71, 163-174. [Google Scholar] [CrossRef] [PubMed]
[32] Brenner, C., Galluzzi, L., Kepp, O. and Kroemer, G. (2013) De-coding Cell Death Signals in Liver Inflammation. Journal of Hepatology, 59, 583-594. [Google Scholar] [CrossRef] [PubMed]
[33] 刘新月, 周璐瑾, 马玉, 王文栋, 郝敏, 常晓彤. Toll样受体2和肠道菌群在高脂饮食诱导的胰岛素抵抗中的作用[J]. 现代预防医学, 2022, 49(10): 1881-1886+1891.
[34] 曹荟哲. 游离脂肪酸致胰岛素抵抗的机制研究[D]: [硕士学位论文]. 兰州: 兰州理工大学, 2017.
[35] DiBaise, J.K., Zhang, H., Crowell, M.D., Krajmalnik-Brown, R., Decker, G.A. and Rittmann, B.E. (2008) Gut Microbiota and Its Pos-sible Relationship with Obesity. Mayo Clinic Proceedings, 83, 460-469. [Google Scholar] [CrossRef] [PubMed]
[36] Dong, X., Liu, H., Chen, F., Li, D. and Zhao, Y. (2014) MiR-214 Promotes the Alcohol-Induced Oxidative Stress via Down-Regulation of Glutathione Reductase and Cytochrome P450 Oxidore-ductase in Liver Cells. Alcohol: Clinical and Experimental Research, 38, 68-77. [Google Scholar] [CrossRef] [PubMed]
[37] Edfeldt, K., Swedenborg, J., Hansson, G.K. and Yan, Z.Q. (2002) Expres-sion of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation. Circulation, 105, 1158-1161. [Google Scholar] [CrossRef] [PubMed]
[38] Hritz, I., Mandrekar, P., Velayudham, A., et al. (2008) The Critical Role of Toll-Like Receptor (TLR) 4 in Alcoholic Liver Disease Is Independent of the Common TLR Adapter MyD88. Hepatology, 48, 1224-1231. [Google Scholar] [CrossRef] [PubMed]
[39] Ishibashi, M., Sayers, S., D’Armiento, J.M., Tall, A.R. and Welch, C.L. (2013) TLR3 Deficiency Protects against Collagen Degradation and Medial Destruction in Murine Atherosclerotic Plaques. Atherosclerosis, 229, 52-61. [Google Scholar] [CrossRef] [PubMed]
[40] Sun, Y., Ishibashi, M., Seimon, T., et al. (2009) Free Cholesterol Accumulation in Macrophage Membranes Activates Toll-Like Receptors and p38 Mitogen-Activated Protein Kinase and Induces Cathepsin K. Circulation Research, 104, 455-465. [Google Scholar] [CrossRef
[41] Albillos, A., de Gottardi, A. and Rescigno, M. (2020) The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy. Journal of Hepatology, 72, 558-577. [Google Scholar] [CrossRef] [PubMed]
[42] Bauer, K.C., Littlejohn, P.T., Ayala, V., Creus-Cuadros, A. and Finlay, B.B. (2022) Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective. Gastroenterology, 162, 1858-1875.e2. [Google Scholar] [CrossRef] [PubMed]
[43] Tripathi, A., Debelius, J., Brenner, D.A., et al. (2018) The Gut-Liver Axis and the Intersection with the Microbiome. Nature Reviews Gastroenterology & Hepatology, 15, 397-411. [Google Scholar] [CrossRef] [PubMed]
[44] Hwang, S., He, Y., Xiang, X., et al. (2020) Interleukin-22 Ame-liorates Neutrophil-Driven Nonalcoholic Steatohepatitis through Multiple Targets. Hepatology, 72, 412-429. [Google Scholar] [CrossRef] [PubMed]
[45] Qiao, Y., Li, X., Zhang, X., et al. (2019) Hepatocellular iNOS Protects Liver from NASH through Nrf2-Dependent Activation of HO-1. Biochemical and Biophysical Research Communica-tions, 514, 372-378. [Google Scholar] [CrossRef] [PubMed]
[46] Song, K., Kwon, H., Han, C., et al. (2020) Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis. Hepatology, 72, 72-87. [Google Scholar] [CrossRef] [PubMed]